PDCD1 and neoplasm: Previous researches suggested that nanovesicles (NVs) overexpressing high‐affinity PD‐1 or SIRPα variants, which could push the limit of current therapeutics, significantly alleviated the immunosuppressive state of tumour and delayed tumour growth (Chen et al., 2022; Rao et al., 2020; Zhang et al., 2018).